AR013529A1 - Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende. - Google Patents

Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende.

Info

Publication number
AR013529A1
AR013529A1 ARP980104820A ARP980104820A AR013529A1 AR 013529 A1 AR013529 A1 AR 013529A1 AR P980104820 A ARP980104820 A AR P980104820A AR P980104820 A ARP980104820 A AR P980104820A AR 013529 A1 AR013529 A1 AR 013529A1
Authority
AR
Argentina
Prior art keywords
prepare
understands
vector
expression
terminally truncated
Prior art date
Application number
ARP980104820A
Other languages
English (en)
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR013529(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of AR013529A1 publication Critical patent/AR013529A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invencion se refiere a RANTES amino-terminalmente truncados. que carecen de amino ácidos NH2-terminal que corresponden a los residuos deamino ácido 1, 1-2, 1-3 o 1-4 de los RANTES de ocurrencia natural y que presentan unaactiv idad antagonista de quimiokina, así como secuencias de ADNque codifican los mismos, su uso en terapia y/o diagnostico de enfermedades, en el cual se requiere una actividad antagonista de los efectos de quimiokina, ycomposiciones farmacéuticasque la comprenden.
ARP980104820A 1997-09-29 1998-09-28 Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende. AR013529A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (en) 1997-09-29 1997-09-29 Amino-terminal truncated c-c chemokines as chemokine antagonist
EP97122471A EP0905240A1 (en) 1997-09-29 1997-12-19 Amino-terminally truncated c-c chemokines as chemokine antagonists
EP98104216A EP0905241A1 (en) 1997-09-29 1998-03-10 Amino-terminally truncated c-c chemokines as chemokine antagonists

Publications (1)

Publication Number Publication Date
AR013529A1 true AR013529A1 (es) 2000-12-27

Family

ID=8227408

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980104819A AR013528A1 (es) 1997-09-29 1998-09-28 PROTEíNA-2 QUIMIOTÁCTICA MONOCíTICA (MCP-2) HUMANA AMINO TERMINALMENTE TRUNCADA, MOLÉCULA DE ADN QUE LA CODIFICA, VECTOR DE EXPRESIoN Y CÉLULA HUÉSPED CORRESPONDIENTES, PROCESO RECOMBINANTE PARA PREPARAR DICHAS PROTEíNAS, USO DE DICHAS PROTEíNAS PARA LA FABRICACIoN DE UN MEDICAMENTO uTIL PARA LA TER
ARP980104820A AR013529A1 (es) 1997-09-29 1998-09-28 Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP980104819A AR013528A1 (es) 1997-09-29 1998-09-28 PROTEíNA-2 QUIMIOTÁCTICA MONOCíTICA (MCP-2) HUMANA AMINO TERMINALMENTE TRUNCADA, MOLÉCULA DE ADN QUE LA CODIFICA, VECTOR DE EXPRESIoN Y CÉLULA HUÉSPED CORRESPONDIENTES, PROCESO RECOMBINANTE PARA PREPARAR DICHAS PROTEíNAS, USO DE DICHAS PROTEíNAS PARA LA FABRICACIoN DE UN MEDICAMENTO uTIL PARA LA TER

Country Status (29)

Country Link
US (5) US6977071B2 (es)
EP (6) EP0906954A1 (es)
JP (2) JP4233214B2 (es)
KR (2) KR100542934B1 (es)
CN (3) CN1233415C (es)
AR (2) AR013528A1 (es)
AT (3) ATE263242T1 (es)
AU (2) AU750341B2 (es)
BG (2) BG64679B1 (es)
BR (2) BR9812565A (es)
CA (2) CA2305017A1 (es)
CY (1) CY1110927T1 (es)
CZ (2) CZ299479B6 (es)
DE (3) DE69822856T2 (es)
DK (3) DK1021541T3 (es)
EA (2) EA003942B1 (es)
EE (2) EE200000152A (es)
ES (3) ES2287601T3 (es)
HK (3) HK1062637A1 (es)
HU (2) HU226414B1 (es)
IL (2) IL135351A (es)
NO (2) NO20001584D0 (es)
NZ (3) NZ516027A (es)
PL (2) PL196427B1 (es)
PT (3) PT1439231E (es)
SK (2) SK286439B6 (es)
UA (2) UA73081C2 (es)
WO (2) WO1999016877A1 (es)
ZA (2) ZA988676B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6534626B1 (en) * 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
DE60030749T2 (de) * 1999-10-25 2007-09-20 Pharis Biotec Gmbh Prozessiertes menschliches chemokin phc-1
EP1167527A1 (en) * 2000-06-22 2002-01-02 Euroscreen S.A. Processed human chemokines PHC-1 and PHC-2
AU2505601A (en) * 1999-11-15 2001-05-30 Wolf-Georg Forssmann Novel use of hcc-2
CA2316405A1 (en) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation of inflammation by protease products
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
US7553483B2 (en) 2001-12-17 2009-06-30 Merck Serono Sa Chemokine mutants acting as chemokine antagonists
WO2004104216A2 (en) * 2003-05-21 2004-12-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4)
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
DK2185719T3 (en) 2007-08-02 2014-02-17 Novimmune Sa ANTI-RANTES ANTIBODIES AND PROCEDURES FOR USE THEREOF
WO2011097567A1 (en) * 2010-02-08 2011-08-11 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Rantes multiplexed assay, rantes variants related to disease, and rantes variants related to enzymatice activity
US9296803B2 (en) 2010-03-11 2016-03-29 Health Research, Inc. Methods and compositions containing Fc fusion proteins for enhancing immune responses
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
EP3813869B1 (en) 2018-05-28 2023-10-18 Université de Genève Ccr5 inhibitor for use in treating a neuroinflammatory disorder that involves cerebral inflammation
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1996017935A2 (en) * 1994-12-08 1996-06-13 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
WO1997025427A1 (en) * 1996-01-12 1997-07-17 Genetics Institute, Inc. Beta-chemokine, h1305 (mcp-2)
WO1997035982A2 (en) * 1996-03-27 1997-10-02 Icos Corporation Monocyte chemotactic protein-5 materials and methods
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
AR013528A1 (es) 2000-12-27
NZ516027A (en) 2003-05-30
AU750606B2 (en) 2002-07-25
CN1148447C (zh) 2004-05-05
DK1439231T3 (da) 2007-11-05
US20050201977A1 (en) 2005-09-15
JP4233214B2 (ja) 2009-03-04
PT1019507E (pt) 2004-06-30
KR20010024213A (ko) 2001-03-26
HUP0003563A3 (en) 2005-11-28
NZ503235A (en) 2002-08-28
EP1439231A3 (en) 2004-12-22
ES2218860T3 (es) 2004-11-16
HK1032425A1 (en) 2001-07-20
KR20010024214A (ko) 2001-03-26
DE69823218T2 (de) 2004-08-26
US20050164936A1 (en) 2005-07-28
KR100560275B1 (ko) 2006-03-10
ATE263242T1 (de) 2004-04-15
CN1271385A (zh) 2000-10-25
HU226414B1 (en) 2008-11-28
IL135351A (en) 2006-08-20
CN1145693C (zh) 2004-04-14
EP1021541B1 (en) 2004-04-14
CN1490049A (zh) 2004-04-21
DE69838188D1 (de) 2007-09-13
JP4230659B2 (ja) 2009-02-25
US6905676B2 (en) 2005-06-14
PL197569B1 (pl) 2008-04-30
EA003942B1 (ru) 2003-10-30
DK1019507T3 (da) 2004-07-19
AU750341B2 (en) 2002-07-18
SK286495B6 (sk) 2008-11-06
ZA988676B (en) 1999-12-03
HUP0003505A3 (en) 2005-11-28
KR100542934B1 (ko) 2006-01-11
PT1439231E (pt) 2007-08-20
SK286439B6 (sk) 2008-10-07
CA2305017A1 (en) 1999-04-08
EE200000151A (et) 2001-02-15
HK1062637A1 (en) 2004-11-19
DK1021541T3 (da) 2004-08-02
CZ20001146A3 (cs) 2000-09-13
AU9442098A (en) 1999-04-23
SK4502000A3 (en) 2000-09-12
BG104267A (en) 2000-11-30
NZ503234A (en) 2002-06-28
EP1439231A2 (en) 2004-07-21
CZ20001147A3 (cs) 2000-09-13
ZA988675B (en) 1999-11-24
US6977071B2 (en) 2005-12-20
PT1021541E (pt) 2004-07-30
CN1233415C (zh) 2005-12-28
HU226468B1 (en) 2008-12-29
US7326411B2 (en) 2008-02-05
PL339545A1 (en) 2000-12-18
NO20001584L (no) 2000-03-27
EP1019507A1 (en) 2000-07-19
EP1439231B1 (en) 2007-08-01
DE69822856T2 (de) 2004-08-19
UA73080C2 (en) 2005-06-15
EP1021541A1 (en) 2000-07-26
WO1999016877A1 (en) 1999-04-08
EP1019507B1 (en) 2004-03-31
EP0906954A1 (en) 1999-04-07
DE69838188T2 (de) 2007-11-22
BR9812394A (pt) 2000-09-12
IL135352A (en) 2006-08-20
HK1032426A1 (en) 2001-07-20
PL196427B1 (pl) 2008-01-31
UA73081C2 (en) 2005-06-15
NO20001609D0 (no) 2000-03-28
ATE368742T1 (de) 2007-08-15
HUP0003505A2 (hu) 2001-02-28
US20030124677A1 (en) 2003-07-03
SK4512000A3 (en) 2000-09-12
CA2304827A1 (en) 1999-04-08
CN1271386A (zh) 2000-10-25
EA200000378A1 (ru) 2000-10-30
CZ299479B6 (cs) 2008-08-06
NO20001609L (no) 2000-03-28
JP2001518296A (ja) 2001-10-16
US20050220790A1 (en) 2005-10-06
BG64679B1 (bg) 2005-11-30
CY1110927T1 (el) 2015-06-10
JP2001518297A (ja) 2001-10-16
WO1999016876A1 (en) 1999-04-08
EA200000379A1 (ru) 2000-10-30
BR9812565A (pt) 2000-08-01
ES2215324T3 (es) 2004-10-01
ATE264390T1 (de) 2004-04-15
US20030119148A1 (en) 2003-06-26
EE200000152A (et) 2001-02-15
BG104266A (en) 2000-11-30
ES2287601T3 (es) 2007-12-16
PL339559A1 (en) 2000-12-18
BG64757B1 (bg) 2006-02-28
CZ299478B6 (cs) 2008-08-06
HUP0003563A2 (hu) 2001-02-28
EP0905241A1 (en) 1999-03-31
EP0905240A1 (en) 1999-03-31
US7338653B2 (en) 2008-03-04
DE69823218D1 (de) 2004-05-19
NO20001584D0 (no) 2000-03-27
DE69822856D1 (de) 2004-05-06
EA003940B1 (ru) 2003-10-30
AU9747498A (en) 1999-04-23

Similar Documents

Publication Publication Date Title
AR013529A1 (es) Rantes amino-terminalmente truncado, moleculas de adn, vector de expresion, celula huesped, proceso recombinante para prepararlo, su uso para preparar un medicamento y composicion farmaceutica que lo comprende.
DK0559884T4 (da) Rekombinante virusvektorer til ekspression i muskelceller
DK0910647T3 (da) Human DNase i hyperaktive varianter
AR026994A1 (es) Nuevas construcciones de expresion en plantas.
MX9207334A (es) Acidos nucleicos peptidicos y formulacion farma- ceutica que los contiene
BR9814276A (pt) Antìgenos de superfìcie
AR010144A1 (es) Molecula de dna recombinante, vector, celula huesped, kit que comprende una molecula de dna recombinante, procedimiento paraseleccionar celulas vegetales transformadas, celula vegetal transgenica, tejido vegetal que comprende celulas vegetales, y uso de una molecu
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
UY23561A1 (es) Procedimiento para la preparacion de tnf-muteinas
AR022358A1 (es) Una composicion de epo, un procedimiento para su obtencion, un preparado farmaceutico que la contiene y un procedimiento para aumentar la actividadespecifica de una composicion de epo
AR003961A1 (es) Moleculas de acido nucleico
DE3672950D1 (de) Thymusextraktfraktionen enthaltende pharmazeutische zusammensetzung.
AR002742A1 (es) Proteina reguladora del tipo adiposo, procedimiento para producir dicha proteina, formulaciones farmaceuticas que la incluyen, molecula de adn aisladaque codifica dicha proteina, vector y celulas recombinantes que comprenden dicho adn
ATE88500T1 (de) Dna-sequenzen, die fuer proteine mit der biologischen aktivitaet der husi-typi-inhibitoren codieren, gentechnologische verfahren zur herstellung dieser proteine und diese proteine enthaltende arzneimittel.
DK0689586T3 (da) VPR-funktion og -aktivitet
ES2091223T3 (es) Nuevas secuencias de adn que codifican polipeptidos semejantes a ancrod y composiciones que comprenden los productos de expresion de las mismas.
DK0811068T3 (da) Humane DNase I varianter
ATE278011T1 (de) Human dnase ii
MX9706429A (es) Variantes de dnasa i humana.

Legal Events

Date Code Title Description
FG Grant, registration